Borges, Á.H. et al. (2025) ‘Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV‐negative adults successfully treated for drug‐susceptible pulmonary tuberculosis: a double‐blind, randomised, placebo‐controlled, phase 2b trial’, Lancet Infectious Diseases, Published online 5 March 2025. doi:10.1016/S1473-3099(24)00814-4.
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, p
- Journal Articles
